Given that Wnt/β-catenin pathway activation is one of the causes of CRC resistance to BRAF inhibition, co-targeting the Wnt/β-catenin pathway using FAK inhibitors may represent a new feasible solution to overcome resistance to BRAF inhibitors with great potential to change the landscape for patients with BRAF mutations [76]. This evidence concerns the gene PTK2 and colorectal carcinoma.